Paul Hudson, Sanofi CEO (Raphael Lafargue/Abaca/Sipa USA; Sipa via AP Images)

AACR21: Sanofi rolls out new da­ta for ear­ly-stage 'non-al­pha' IL-2. Ear­ly feed­back? In­ter­est­ing, but most­ly meh

When Paul Hud­son over at Sanofi inked a $2.5 bil­lion buy­out of can­cer play­er Syn­thorx in late 2019, one of the cen­ter­pieces of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.